Welcome to our dedicated page for Parkervision SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for ParkerVision, Inc. (PRKR), a Florida corporation focused on radio-frequency (RF) technologies for advanced wireless communication systems. Through its periodic and current reports, ParkerVision provides detailed information on its operations, financial condition, litigation posture, and capital-raising activities.
Investors can use ParkerVision’s annual reports on Form 10-K and quarterly reports on Form 10-Q to review its RF technology and licensing focus, operating expenses, net losses, contingent payment obligations, and cash flows. These filings also include risk factor discussions that the company references in its press releases, covering topics such as outcomes of patent litigation, interpretations of patent law and claim scope, decisions by the Patent Trial and Appeal Board (PTAB), and market conditions affecting financing.
Current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe registered direct offerings of common stock under ParkerVision’s effective shelf registration statement on Form S-3, including sales to accredited investors and to a director. These filings outline subscription agreements, offering prices, aggregate purchase amounts, and legal opinions regarding the issuance of securities. Other 8-Ks furnish earnings press releases that summarize quarterly and year-to-date financial results and provide context for changes in operating expenses and contingent payment obligations.
Through this filings page, users can access ParkerVision’s real-time updates as they are filed with EDGAR, including 10-K, 10-Q, and 8-K reports, as well as registration statements and prospectus supplements related to its shelf registration. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections such as litigation disclosures, capital structure changes, and risk factors, and make it easier to interpret complex legal and financial language without replacing the full primary documents.
ParkerVision, Inc. filed a prospectus supplement tied to an existing resale registration covering up to 16,809,295 shares of common stock. These shares include stock issued in prior financings and services, as well as shares issuable upon conversion of earlier convertible notes and upon exercise of warrants held by Aspire Capital Fund LLC and Tailwinds Research Group LLC. The company will not receive proceeds from stockholder resales, but could receive up to $3,900,000 in gross proceeds if the Aspire and Tailwinds warrants are exercised for cash.
The attached current report describes new equity incentives for executives under the 2019 Long-Term Incentive Plan. The Compensation Committee granted a performance-based stock option for up to 8,000,000 shares to the CEO and up to 500,000 shares to the CFO, both with a five-year performance period and a ten-year term, at an exercise price of $0.24 per share. Vesting depends mainly on cumulative net cash from patent enforcement actions, with automatic acceleration if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares and a 2.5% cost-of-living salary increase, matching a similar increase for the CEO.
ParkerVision, Inc. filed a prospectus supplement covering the resale of up to 18,014,164 shares of common stock by existing holders. These shares come from prior convertible notes, consulting share issuances, and a warrant granted for services. The company will not receive any proceeds from stockholder resales, but may receive up to $180,000 if a service-related warrant is exercised for cash, which would be used for working capital and general corporate purposes.
The attached current report also describes new equity compensation for executives. The CEO received a performance-based option for up to 8,000,000 shares and the CFO received performance-based options for up to 500,000 shares, all at an exercise price of $0.24 per share, with vesting tied to net cash from patent enforcement and certain market capitalization or change-of-control triggers. The CFO also received a separate time-based option for up to 500,000 shares and both executives were granted a 2.5% cost-of-living salary increase.
ParkerVision, Inc. files a prospectus supplement covering the resale by existing holders of up to 17,189,660 shares of common stock previously registered under earlier shelf and resale statements. The company will not receive proceeds from these stockholder resales, but may receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from stock sales or warrant exercises under its agreement with Aspire Capital, which it expects to use for patent enforcement and general corporate purposes.
The attached report also discloses new performance-based stock option grants under the 2019 plan: up to 8,000,000 shares for the CEO and 500,000 shares for the CFO, vesting over a five-year performance period tied to net cash from patent enforcement, with accelerated vesting if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also receives a time-based option for up to 500,000 shares and both executives receive a 2.5% cost-of-living base salary increase.
ParkerVision, Inc. updates its resale prospectus covering up to 12,800,000 shares of common stock, which may be sold from time to time by existing selling stockholders. The company will not receive proceeds from these resales, but could receive up to $800,000 in gross proceeds if an associated warrant is exercised for cash, which it expects to use for patent enforcement actions and general working capital.
The company also approved new nonqualified stock option grants under its 2019 Long-Term Incentive Plan. The CEO received a performance-based option for up to 8,000,000 shares and the CFO a performance-based option for up to 500,000 shares, both with a five-year performance period and a ten-year term, at an exercise price of $0.24 per share. Vesting is tied to cumulative net cash from patent enforcement actions and may accelerate if market capitalization reaches $1 billion for twenty consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares vesting over two years, and both executives will receive a 2.5% cost-of-living base salary increase effective April 15, 2026.
ParkerVision, Inc. reported new compensation awards for its top executives. On January 22, 2026, the board’s compensation committee granted performance-based stock options under the 2019 Long-Term Incentive Plan, including an option to purchase up to 8,000,000 shares for CEO Jeffrey Parker and an option to purchase up to 500,000 shares for CFO Cynthia French.
The options have a five-year performance period with quarterly measurement dates, a ten-year term, and an exercise price of $0.24 per share, based on the last sale price on the grant date. Vesting depends on cumulative net cash the company receives from its patent enforcement actions after specified fees and repayments.
These performance options fully vest automatically if the company’s market capitalization reaches at least $1 billion for 20 consecutive trading days or upon a change in control. The committee also granted the CFO a separate time-based option for up to 500,000 shares at $0.24 per share, vesting in four equal biannual installments over two years beginning July 22, 2026, and approved a 2.5% cost-of-living increase in the base salaries of the CEO and CFO effective April 15, 2026.
ParkerVision, Inc. filed a prospectus supplement that continues to permit the resale by existing shareholders of up to 9,387,500 shares of common stock. These shares include 2,843,750 shares already issued under prior securities purchase agreements, 6,343,750 shares issuable upon conversion or interest payments on convertible notes at a fixed conversion price of $0.16 per share, and 200,000 shares issuable upon exercise of options granted for services. The company will not receive proceeds from shareholder resales but could receive up to $42,620 if the options are exercised for cash.
The supplement also incorporates a new Form 8-K, which reports that on November 24, 2025 ParkerVision completed a separate registered offering and sale of 16,481,579 common shares to accredited investors for an aggregate purchase price of $3,461,132, using its shelf registration statement. No underwriters, placement agents, brokers, or finders were engaged, and no commissions or fees were paid.
ParkerVision, Inc. has a prospectus supplement allowing the selling shareholders to resell up to 16,638,353 shares of common stock issuable upon conversion and interest payments on certain 2022 convertible notes with a fixed conversion price of $0.13 per share. The supplement incorporates a new Form 8-K that reports a separate capital raise completed on November 24, 2025.
In that transaction, the company sold 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of
ParkerVision, Inc. is registering for resale up to 1,578,946 shares of common stock under a prospectus supplement that also incorporates a recent equity financing update. The registered amount includes 1,052,631 outstanding shares of common stock and 526,315 shares issuable upon exercise of warrants issued under a December 14, 2021 securities purchase agreement. The company will not receive any proceeds from resale of these shares, but could receive up to $526,315 in gross proceeds if the warrants are exercised for cash, which it plans to use for general working capital, including litigation expenses. Separately, ParkerVision completed a primary offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, conducted off its shelf registration statement without underwriters or fees.
ParkerVision, Inc. has filed a prospectus supplement covering the resale of up to 13,342,953 shares of common stock by selling stockholders. These shares include 7,962,722 shares issued under prior securities purchase agreements, 3,230,942 shares plus 1,619,289 warrant shares from March 29, 2021 agreements, and 530,000 shares issued as payment for services. The company will not receive proceeds from resales, but could receive up to $2,833,756 in gross proceeds if the related warrants are exercised for cash, which it expects to use for working capital and litigation expenses.
The supplement also attaches a Form 8-K describing a completed offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, conducted off the company’s shelf registration statement. No underwriters, placement agents, brokers, or finders were used, and no commissions or fees were paid in connection with this primary offering.
ParkerVision, Inc. has filed a prospectus supplement tied to an existing resale registration that permits selling stockholders to resell up to 5,871,584 shares of its common stock issued under prior securities purchase agreements. The company will not receive any proceeds from these resale transactions. The supplement updates the prospectus by incorporating a new Form 8-K.
The attached Form 8-K reports that on November 24, 2025, ParkerVision completed an offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132 under its shelf registration statement on Form S-3. The company conducted this primary offering without underwriters, placement agents, brokers, or finders and paid no commissions or fees.